Forecast Period 
Market Size (Base Year) 
Market Size (Forecast Year)
CAGRMiddle East and Africa Genital Warts Market, By Morphology (Cauliflower-Like, Smooth Papular, Keratotic, and Flat Warts), Type (Prevention, Diagnostics, Treatment), Cause (HPV 6, HPV 11, Others), Location (Vulva, Cervix Uteri, Urethra, Anus, Scrotum), Gender (Male and Female), Dosage (Cream, Gel, Ointment, Intramuscularly and Others), End-User (Hospitals, Diagnostic Centers, Surgical Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Pharmacy Stores and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel and rest of the Middle East and Africa) Market Trends and Forecast to 2028.
Market Analysis and Insights: Middle East and Africa Genital Warts Market
Middle East and Africa genital warts market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.7% in the forecast period of 2021 to 2028 and is expected to reach USD 320.38 million by 2028 from USD 228.90 million in 2020. The rising incidence of STDs and the growth of novel technological advancements for genital warts are likely to be the major drivers which propel the demand of the market in the forecast period.
Genital warts are one of the most recurrent types of sexually transmitted infections. The human papillomavirus is the virus responsible for causing genital warts. People will get infected with at least one type of human papillomavirus (HPV) at some point during their lives. Genital warts affect most of the moist tissues in the genital areas of male and female patients. Although the genital infection is asymptomatic, it's frequently recognized as genital warts due to the onset of symptoms. It is estimated that around 1% of sexually active men and women in the United States have genital warts.
Genital warts are caused due to the human papillomavirus (HPV). There are around 30-40 strains of HPV. However, only a few of the strains cause genital warts. The virus is easily transmittable through skin-to-skin contact. Hence it's considered a sexually transmitted infection (STI). The Center for Disease Control and Prevention (CDC) says that people get genital warts due to the mutant activity of HPV.
Various factors suchs as lack of sanitation and hygiene in developing countries of the Middle East, surge in prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections, rise in patients, rise in government initiatives and awareness programs, and use of cryotherapy for genital warts treatment is expected to drive the Middle East and Africa genital warts market. However, the side effects noticed while undergoing treatment for genital warts and lack of patient and consumer awareness, and lack of funds for the development of diagnostic centers are the restraints that are expected to hinder the genital warts market growth.
Moreover, the rise in clinical trials, rise in healthcare expenditure and strategic initiatives by market players, and huge market potential in developing countries bolsters the genital warts market growth. On the other hand, the rise in product recalls associated with vaccines, and topical administration of genital warts, and patient compliance regarding the use of vaccines are the restraints that can hinder the market growth.
The Middle East and Africa genital warts market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Genital Warts Market Scope and Market Size
The Middle East and Africa genital warts market is segmented on the basis of morphology, type, cause, location, gender, dosage, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of morphology, the Middle East and Africa genital warts market is segmented into flat warts, smooth papular, cauliflower-like, and keratotic. In 2021, the cauliflower-like segment is expected to dominate the Middle East and Africa genital warts market due to the rise in cases of genital warts due to the cauliflower morphology.
- On the basis of type, the Middle East and Africa genital warts market is segmented into prevention, diagnostics and In 2021, the prevention segment is expected to dominate the Middle East and Africa genital warts market due to the rise in awareness programs for prevention and treatment of genital warts in male and female patients, via seminars and conferences.
- On the basis of cause, the Middle East and Africa genital warts market is segmented into HPV 6, HPV 11, and others. In 2021, the HPV 6 segment is expected to dominate the Middle East and Africa genital warts market, owing to the HPV 6 strain causing 90% of genital warts in female patients in Africa
- On the basis of location, the Middle East and Africa genital warts market is segmented into cervix uteri, urethra, anus, vulva, and scrotum. In 2021, the vulva segment is expected to dominate the Middle East and Africa genital warts market because the prevalence rate in women is higher than in men.
- On the basis of gender, the Middle East and Africa genital warts market is segmented into male and female. In 2021, the female segment is expected to dominate the Middle East and Africa genital warts market due to the females aged 21-29 years suffering from genital warts and low immunity in women.
- On the basis of dosage, the Middle East and Africa genital warts market is further sub-segmented into cream, gel, ointment, intramuscularly, and others. In 2021, the cream segment is expected to dominate the Middle East and Africa genital warts market due to increased acceptance of Condylox by the patients of the Middle East and Africa.
- On the basis of end-users, the Middle East and Africa genital warts market is segmented into hospitals, diagnostic centers, surgical centers, ambulatory surgical centers, and others. In 2021, the hospital's segment is expected to dominate the Middle East and Africa genital warts market as hospitals patients have all the facilities as they can directly contact doctors and dermatologists who can diagnose the disease and cure the warts disease and presence of healthcare reimbursement.
- On the basis of distribution channels, the Middle East and Africa genital warts market is segmented into direct tender, pharmacy stores, and others. In 2021, the direct tender segment is expected to dominate the Middle East and Africa genital warts market as there is no requirement of the prescription of doctors and a rise in a number of customers and contracts with healthcare organizations and wholesalers.
Middle East and Africa Genital Warts Market Country Level Analysis
The Middle-East and Africa genital warts market is analyzed, and market size information is provided by product and services, sample type, process, application, compound library size, end-user, and distribution channel
The countries covered in the Middle-East and Africa genital warts market report are South Africa, Saudi Arabia, UAE, Egypt, Israel, and the Rest of the Middle East and Africa.
The Middle East and Africa are expected to grow with a substantial growth rate in the forecast period of 2020 to 2028 as Middle East and Africa counties are major developing countries and focus on increasing R&D activities in the pharma and biotech sector and increase outsourcing services. South Africa is expected to dominate in the market in the Middle East and Africa market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
The Growth Potential For The Genital Warts In Emerging Economies And The Strategic Initiatives By Market Players Are Creating New Opportunities In The Middle East And Africa Genital Wartsmarket.
The Middle East and Africa genital warts market also provide you with detailed market analysis for every country's growth in a particular industry with the genital warts treatment products sales, impact of advancement in genital warts, and changes in regulatory scenarios with their support for the Middle East and Africa genital warts market. The data is available for the historic period 2010 to 2019.
Competitive Landscape and the Middle East and Africa Genital wartsMarket Share Analysis
Middle East and Africa genital warts market competitive landscape provide details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the Middle East and Africa genital warts market.
The major companies providing the Middle East and Africa genital warts are Bausch Health Companies Inc., Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc, Taro Pharmaceutical Industries Ltd, Glenmark Pharmaceutical Inc., USA (a subsidiary of Glenmark Pharmaceuticals Ltd.), GlaxoSmithKline plc, Fotona, Orgenesis Inc, Perrigo Company plc among others.
The strategic initiatives by market players, along with new technological advancements for genital warts, is bridging the gap for chronic wounds treatment.
For instance,
- In June 2021, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., had declared the U.S. FDA approval for GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of HPV-related cervical, vaginal, vulvar, anal, oropharyngeal, and other head and neck cancers. The FDA approval received would result in addressing the unmet clinical needs for the patients, increased distribution of the vaccine in hospitals and cancer research institutes for the rise in product sales
Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the Middle East and Africa genital warts market, which also provides the benefit for an organization to improve their offering for treatment products.
